

CASE STUDY

RCA CTO

DYNAMX

CORONARY BIOADAPTOR

CASE OVERVIEW

- CTO in the RCA treated with DynamX Coronary Bioadaptor
- Case performed by Antonio Colombo, MD and Gabriele Gasparini, MD, Humanitas Research Hospital, Italy
- Outcomes
 - DynamX demonstrates acute performance similar to DES

PATIENT HISTORY

Demographics

- Age: 51 years old
- Gender: Male
- BMI: 28

Risk Factors

- Dyslipidemia
- Ex smoker
- HTN

Clinical History

- Silent ischemia
- CABG refusal

Diagnostic tests

- EKG: sinus rhythm, q wave in DIII
- TTE: basal inferior akinesia, preserved LVEF
- Minimal carotid artery intimal thickening
- Stress TTE: transient lateral and posterior septal hypokinesia
- SPECT: inferoposterolateral inducible 10% ischemia
- S/p anterograde RCA CTO PCI


LESION AT BASELINE

RCA CTO





LESION CROSSING

Successful antegrade wire escalation (AWE) and lesion crossing with Gaia 2 on FineCross (Gladius failure). A balloon was inflated in the sinoatrial (SA) node artery to support the guiding catheter



LESION PREPARATION

Multiple inflations with a semi-compliant balloon 2.0 mm x 30 mm





CASE STUDY
RCA CTO



BIOADAPTOR IMPLANTS

DynamX bioadaptor 3.0 mm x 38 mm at 16 atm was implanted distally

DynamX bioadaptor 3.5 mm x 18 mm at 20 atm was implanted proximally with minimal overlap



FINAL RESULT



International (OUS) Use Only. CAUTION: The law restricts these devices to sale by or on the order of a physician. Indications, contraindications, warnings and instructions for use can be found in the product labeling supplied with each device. Case study offered by the physician is based on their experience and is at their discretion. Medical decisions for your patients are to be based upon their condition and your medical judgment.

Elixir and DynamX are registered trademarks in the US and internationally for Elixir Medical Corporation.

DynamX Coronary Bioadaptor System is CE Mark approved. ©2024 Elixir Medical. All rights reserved.



PMN 869 Rev C